
Shahnaz Sali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1674157/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiology, Clinical and Laboratory Manifestations, and Outcomes of Brucellosis Among 104 Patients in Referral Hospitals of Tehran, Iran. Archives of Clinical Infectious Diseases, 2021, 16, .	0.1	2
2	The Importance of Screening Strongyloides stercoralis Infection in Solid Organ Transplant Donors and Recipients. Archives of Clinical Infectious Diseases, 2021, 16, .	0.1	0
3	An investigation into the Effects of Intravenous Vitamin C on Pulmonary CT Findings and Clinical Outcomes of Patients with COVID 19 Pneumonia A Randomized Clinical Trial. Urology Journal, 2021, , 6863.	0.3	12
4	Descriptive Analysis of COVID-19 among Health Care Workers in a Tertiary Center in Iran Tanaffos, 2021, 20, 246-252.	0.5	0
5	SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clinical Infectious Diseases, 2020, 70, 2206-2212.	2.9	19
6	COVIDâ€19 and kidney transplant recipients. Transplant Infectious Disease, 2020, 22, e13413.	0.7	22
7	Evaluation of the Efficacy of Arbidol in Comparison with the Standard Treatment Regimen of Hospitalized Patients with Covid-19: A Randomized Clinical Trial. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	2
8	Sofosbuvir for the Treatment of COVID-19 Patients: Is It a Promising Therapeutic Medicine for the Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2?. Avicenna Journal of Medical Biochemistry, 2020, 8, 133-135.	0.5	0
9	Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	Ο
10	VIRAL LOAD AND NUCLEOTIDE SUBSTITUTIONS IN HEPATITIS B VIRUSES DERIVED FROM CHRONIC HBV PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019046.	0.5	1
11	Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-analysis. Journal of Clinical and Translational Hepatology, 2019, X, 1-16.	0.7	7
12	Tenofovir Alafenamide: A New Drug With Various Ambiguous Aspects in Treatment of Chronic Hepatitis B Infection. Archives of Clinical Infectious Diseases, 2019, In Press, .	0.1	0
13	Phylogenetic Analysis of Virus among Household Members with HBV Chronic Infection. Avicenna Journal of Medical Biotechnology, 2019, 11, 221-228.	0.2	2
14	A Forty- Four Year - Old Immunized Woman with Maculopapular and Petechial Rash, Diagnosed as Measles: An Extremely Rare Presentation. International Journal of Infection, 2018, 5, .	0.4	2
15	Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunology Letters, 2017, 190, 206-212.	1.1	9
16	Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepatitis Monthly, 2016, 16, e35810.	0.1	30
17	Comparison of Vitamin D Levels in Naive, Treated, and Inactive Carriers with Chronic Hepatitis B Virus. Journal of Clinical and Translational Hepatology, 2016, 4, 306-309.	0.7	7
18	Multiple intracranial tuberculomas in a post-kidney transplant patient. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2016, 27, 135.	0.4	4

Shahnaz Sali

#	Article	IF	CITATIONS
19	Tumor Necrosis Factor-α-308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis. Hepatitis Monthly, 2016, 16, e33537.	0.1	5
20	Association of Plasma Levels of Vitamin D With Chronic Hepatitis B Infection. Hepatitis Monthly, 2016, 16, e35525.	0.1	3
21	Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection. Hepatitis Monthly, 2016, 16, e37927.	0.1	11
22	Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience. Global Journal of Health Science, 2015, 7, 101-7.	0.1	5
23	Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?. Diagnostic Microbiology and Infectious Disease, 2015, 82, 114-119.	0.8	10
24	An Unusual Presentation of Tuberculous Meningitis. Archives of Clinical Infectious Diseases, 2015, 10, .	0.1	1
25	Non-Invasive Histologic Markers of Liver Disease in Patients With Chronic Hepatitis B. Hepatitis Monthly, 2014, 14, e14228.	0.1	23
26	A rare case presentation of oral actinomycosis. International Journal of Mycobacteriology, 2013, 2, 187-189.	0.3	10
27	Occupational Exposure to Blood Borne Viruses Among Healthcare Workers in a Tertiary Care Referral Hospital in Tehran. Hepatitis Monthly, 2013, 13, e12201.	0.1	1
28	Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepatitis Monthly, 2013, 13, e8743.	0.1	10
29	Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Hepatitis Monthly, 2012, 12, e6151.	0.1	26
30	Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis	0.7	17

Effect of levamisole supplementation on he patients. Nephrology, 2008, 13, 376-379.